Survival of metastatic breast carcinoma patients over a 20‐year period

Abstract

The distribution of subvertical grooves on interproximal wear dental facets from the El Sidrón (Asturias, Spain) Neandertals is described and analyzed. Out of 93 teeth, 64.5% present subvertical grooves, including a high frequency (50%) on the anterior dentition. Contrary to some studies, subvertical grooves from adjacent facets perfectly overlap each other and do not interdigitate, probably forming small channels. Both the facet and the groove surface share the same polished appearance, suggesting a common origin. Statistical analyses reveal that the number of grooves is neither dependent on the degree of occlusal wear, nor on the position on the tooth or the individual's age. However, facet width is an important factor determining the number of subvertical grooves. The etiology of subvertical grooves formation on Neandertal teeth remains unclear. Am J Phys Anthropol, 2010. © 2010 Wiley‐Liss, Inc.

Breast cancer lung metastasis: Molecular biology and therapeutic implications

“…5,6 The 5-y survival rate of breast cancer patients who recurred with distant metastasis is less than 20%. 7,8 The lung, bone, and liver, are the most common metastatic target sites for breast cancer. In fact, approximately 60% of metastatic breast cancer patients suffer lung or bone metastasis in their life.…”

“…In fact, approximately 60% of metastatic breast cancer patients suffer lung or bone metastasis in their life. 7 BLBC is specifically prone to metastasize to the lung. Life expectancy is low when this occurs, with median survival only 22 months after treatment for lung metastasis.…”

Self-reported health-related quality of life is an independent predictor of chemotherapy treatment benefit and toxicity in women with advanced breast cancer

“…Oncologists consider a range of patient and disease characteristics such as age, performance status, disease-free interval, hormone receptor status, disease burden and prior adjuvant treatments (Hortobagyi et al, 1983;Gennari et al, 2005;Largillier et al, 2008). More recently, patient's self-reported health-related QL has also been recognised as predictive of survival (Gotay et al, 2008;Quinten et al, 2009).…”

Fallopian tube metastasis in a patient with a history of breast cancer

“…Another 30 percent of women with early-stage breast cancer at diagnosis would develop distant metastatic disease after treatment [1]. Metastatic breast cancer is unlikely to be cured; median survival is approximately 18 to 24 months, though this varies based on subtype of tumor, sites of metastatic involvement, and burden of metastatic disease [2]. The most common metastasic sites are the lung, liver, brain, and bone [3].…”